Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt 1.29
INCY's Cash to Debt is ranked lower than
76% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: 58.56 vs. INCY: 1.29 )
Ranked among companies with meaningful Cash to Debt only.
INCY' s Cash to Debt Range Over the Past 10 Years
Min: 0.35  Med: 1.22 Max: No Debt
Current: 1.29
Equity to Asset 0.21
INCY's Equity to Asset is ranked lower than
88% of the 707 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. INCY: 0.21 )
Ranked among companies with meaningful Equity to Asset only.
INCY' s Equity to Asset Range Over the Past 10 Years
Min: -1.83  Med: 0.07 Max: 0.79
Current: 0.21
-1.83
0.79
Interest Coverage 2.17
INCY's Interest Coverage is ranked lower than
92% of the 365 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. INCY: 2.17 )
Ranked among companies with meaningful Interest Coverage only.
INCY' s Interest Coverage Range Over the Past 10 Years
Min: 0.02  Med: 0.32 Max: 1.11
Current: 2.17
0.02
1.11
F-Score: 7
Z-Score: 10.73
M-Score: -2.64
WACC vs ROIC
6.09%
127.12%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 10.91
INCY's Operating margin (%) is ranked higher than
79% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -77.71 vs. INCY: 10.91 )
Ranked among companies with meaningful Operating margin (%) only.
INCY' s Operating margin (%) Range Over the Past 10 Years
Min: -4064.53  Med: -78.07 Max: 8.27
Current: 10.91
-4064.53
8.27
Net-margin (%) 5.70
INCY's Net-margin (%) is ranked higher than
75% of the 730 Companies
in the Global Biotechnology industry.

( Industry Median: -78.92 vs. INCY: 5.70 )
Ranked among companies with meaningful Net-margin (%) only.
INCY' s Net-margin (%) Range Over the Past 10 Years
Min: -4565.45  Med: -110.46 Max: 0.87
Current: 5.7
-4565.45
0.87
ROE (%) 48.80
INCY's ROE (%) is ranked higher than
98% of the 857 Companies
in the Global Biotechnology industry.

( Industry Median: -32.89 vs. INCY: 48.80 )
Ranked among companies with meaningful ROE (%) only.
INCY' s ROE (%) Range Over the Past 10 Years
Min: 14.59  Med: 14.59 Max: 14.59
Current: 48.8
ROA (%) 5.06
INCY's ROA (%) is ranked higher than
85% of the 939 Companies
in the Global Biotechnology industry.

( Industry Median: -28.03 vs. INCY: 5.06 )
Ranked among companies with meaningful ROA (%) only.
INCY' s ROA (%) Range Over the Past 10 Years
Min: -70.43  Med: -18.85 Max: 0.72
Current: 5.06
-70.43
0.72
ROC (Joel Greenblatt) (%) 109.70
INCY's ROC (Joel Greenblatt) (%) is ranked higher than
95% of the 902 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. INCY: 109.70 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
INCY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -4569.91  Med: -376.81 Max: 63.36
Current: 109.7
-4569.91
63.36
Revenue Growth (3Y)(%) 20.70
INCY's Revenue Growth (3Y)(%) is ranked higher than
75% of the 485 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. INCY: 20.70 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
INCY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -61.4  Med: 18.80 Max: 194.1
Current: 20.7
-61.4
194.1
EBITDA Growth (3Y)(%) 28.60
INCY's EBITDA Growth (3Y)(%) is ranked higher than
81% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. INCY: 28.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
INCY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -31.7  Med: -8.20 Max: 221.2
Current: 28.6
-31.7
221.2
» INCY's 10-Y Financials

Financials (Next Earnings Date: 2016-08-09)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

INCY Guru Trades in Q2 2015

Joel Greenblatt 10,363 sh (New)
Jim Simons 275,000 sh (New)
Vanguard Health Care Fund 9,411,543 sh (-7.50%)
Ken Fisher 13,695 sh (-7.90%)
» More
Q3 2015

INCY Guru Trades in Q3 2015

Paul Tudor Jones 9,555 sh (New)
John Burbank 309,627 sh (New)
Ken Fisher 14,495 sh (+5.84%)
Vanguard Health Care Fund 9,233,028 sh (-1.90%)
Joel Greenblatt 4,861 sh (-53.09%)
Jim Simons 33,200 sh (-87.93%)
» More
Q4 2015

INCY Guru Trades in Q4 2015

George Soros 4,200 sh (New)
Frank Sands 4,420,966 sh (New)
Vanguard Health Care Fund 9,615,828 sh (+4.15%)
Ken Fisher 14,818 sh (+2.23%)
Samuel Isaly 431,500 sh (unchged)
Jim Simons Sold Out
John Burbank Sold Out
Joel Greenblatt Sold Out
Paul Tudor Jones 8,513 sh (-10.91%)
» More
Q1 2016

INCY Guru Trades in Q1 2016

Joel Greenblatt 52,500 sh (New)
Jim Simons 304,000 sh (New)
Paul Tudor Jones 77,400 sh (+809.20%)
Vanguard Health Care Fund 16,227,748 sh (+68.76%)
Ken Fisher 14,839 sh (+0.14%)
George Soros Sold Out
Frank Sands 3,819,401 sh (-13.61%)
Samuel Isaly 429,400 sh (-0.49%)
» More
» Details

Insider Trades

Latest Guru Trades with INCY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:BMRN, OTCPK:GIKLY, OTCPK:NVZMY, OTCPK:UCBJY, OTCPK:ALIOY, NAS:MDVN, OTCPK:GMXAY, NAS:VRTX, NAS:JAZZ, NAS:ALKS, NAS:SGEN, NAS:ALNY, NAS:UTHR, OTCPK:SBMFF, NAS:ANAC, NAS:ALXN, NAS:TSRO, NAS:ACAD, NAS:TECH, NAS:ICPT » details
Traded in other countries:ICY.Germany,
Incyte Corp is a biopharmaceutical company. It discovers, develops and commercializes proprietary small molecule drugs to treat serious unmet medical needs, mainly in oncology.

Incyte Corp was incorporated in Delaware in 1991. It is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary small molecule drugs to treat serious unmet medical needs, mainly in oncology. Its pipeline includes compounds in various stages, ranging from preclinical to late stage development, and a commercialized product, JAKAFI (ruxolitinib). The Company faces competition from organizations, particularly fully integrated pharmaceutical companies that are pursuing pharmaceuticals that are competitive with JAKAFI and its drug candidates. Its trademaks include Incyte and JAKAFI. The Company's ongoing research and development activities and any manufacturing and marketing of JAKAFI and its drug candidates are subject to extensive regulation by numerous governmental authorities in the United States and other countries.

Top Ranked Articles about Incyte Corp

Market-Beating Vanguard Health Care Fund Adds Shares to 5 Positions Solid growth has attended the sector until this year
Against a backdrop of solid growth for the sector, the outperforming Vanguard Health Care Fund (Trades, Portfolio) replenished its portfolio in the first quarter with increases in 27 holdings and reductions or removal of 28 holdings. Read more...
Vanguard Boosts Stake in Incyte in 1st Quarter Guru sells holdings in CVS Health, Edwards Lifesciences, Monsanto
Vanguard Health Care Fund continued a streak of double-digit returns in 2015 with returns of 12.65%. That is below the fund’s returns levels of 2014 (28.52%) and 2013 (43.19%), but it is still in double digits, which was a considerable achievement in 2015’s challenging investing environment. Read more...
Frank Sands Acquires Stake in Netflix Guru adds to positions in Amazon and Under Armour
Much of the significant fourth-quarter investment activity from Frank Sands (Trades, Portfolio), CEO and CIO of Sands Capital Management, an investment management firm that invests in quality growth businesses across the globe, was in familiar names in North America. Read more...
The Best-Performing Stocks Among Vanguard Health Care Fund's Holdings Prothena Corp. tops the list with a 148% return year-to-date
Jean M. Hynes has managed the Vanguard Health Care Fund (Trades, Portfolio) (VGHCX) since 2008, which is now composed of 82 stocks. The following are the stocks in the portfolio with the highest performance since the beginning of the year. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 345.64
INCY's P/E(ttm) is ranked lower than
95% of the 254 Companies
in the Global Biotechnology industry.

( Industry Median: 29.09 vs. INCY: 345.64 )
Ranked among companies with meaningful P/E(ttm) only.
INCY' s P/E(ttm) Range Over the Past 10 Years
Min: 260.28  Med: 2085.60 Max: 5661.5
Current: 345.64
260.28
5661.5
Forward P/E 476.19
INCY's Forward P/E is ranked lower than
100% of the 71 Companies
in the Global Biotechnology industry.

( Industry Median: 21.32 vs. INCY: 476.19 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 345.64
INCY's PE(NRI) is ranked lower than
95% of the 229 Companies
in the Global Biotechnology industry.

( Industry Median: 29.71 vs. INCY: 345.64 )
Ranked among companies with meaningful PE(NRI) only.
INCY' s PE(NRI) Range Over the Past 10 Years
Min: 260.28  Med: 2085.60 Max: 5661.5
Current: 345.64
260.28
5661.5
Price/Owner Earnings (ttm) 170.10
INCY's Price/Owner Earnings (ttm) is ranked lower than
87% of the 130 Companies
in the Global Biotechnology industry.

( Industry Median: 34.88 vs. INCY: 170.10 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
INCY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 10.73  Med: 25.27 Max: 3235.14
Current: 170.1
10.73
3235.14
P/B 71.12
INCY's P/B is ranked lower than
99% of the 1075 Companies
in the Global Biotechnology industry.

( Industry Median: 3.25 vs. INCY: 71.12 )
Ranked among companies with meaningful P/B only.
INCY' s P/B Range Over the Past 10 Years
Min: 53.56  Med: 157.15 Max: 391.93
Current: 71.12
53.56
391.93
P/S 18.88
INCY's P/S is ranked lower than
60% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: 12.77 vs. INCY: 18.88 )
Ranked among companies with meaningful P/S only.
INCY' s P/S Range Over the Past 10 Years
Min: 7.13  Med: 22.38 Max: 239.71
Current: 18.88
7.13
239.71
PFCF 102.50
INCY's PFCF is ranked lower than
86% of the 147 Companies
in the Global Biotechnology industry.

( Industry Median: 27.27 vs. INCY: 102.50 )
Ranked among companies with meaningful PFCF only.
INCY' s PFCF Range Over the Past 10 Years
Min: 6.56  Med: 143.90 Max: 1176.61
Current: 102.5
6.56
1176.61
POCF 86.84
INCY's POCF is ranked lower than
85% of the 205 Companies
in the Global Biotechnology industry.

( Industry Median: 22.90 vs. INCY: 86.84 )
Ranked among companies with meaningful POCF only.
INCY' s POCF Range Over the Past 10 Years
Min: 6.52  Med: 153.87 Max: 775.18
Current: 86.84
6.52
775.18
EV-to-EBIT 172.28
INCY's EV-to-EBIT is ranked lower than
94% of the 295 Companies
in the Global Biotechnology industry.

( Industry Median: 20.49 vs. INCY: 172.28 )
Ranked among companies with meaningful EV-to-EBIT only.
INCY' s EV-to-EBIT Range Over the Past 10 Years
Min: -8436.1  Med: -8.70 Max: 1546.6
Current: 172.28
-8436.1
1546.6
EV-to-EBITDA 116.88
INCY's EV-to-EBITDA is ranked lower than
92% of the 319 Companies
in the Global Biotechnology industry.

( Industry Median: 17.75 vs. INCY: 116.88 )
Ranked among companies with meaningful EV-to-EBITDA only.
INCY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -662.5  Med: -6.80 Max: 2618.5
Current: 116.88
-662.5
2618.5
Current Ratio 4.67
INCY's Current Ratio is ranked higher than
51% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. INCY: 4.67 )
Ranked among companies with meaningful Current Ratio only.
INCY' s Current Ratio Range Over the Past 10 Years
Min: 1.51  Med: 4.67 Max: 21.14
Current: 4.67
1.51
21.14
Quick Ratio 4.66
INCY's Quick Ratio is ranked higher than
53% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: 4.24 vs. INCY: 4.66 )
Ranked among companies with meaningful Quick Ratio only.
INCY' s Quick Ratio Range Over the Past 10 Years
Min: 1.51  Med: 4.66 Max: 21.14
Current: 4.66
1.51
21.14
Days Inventory 23.92
INCY's Days Inventory is ranked higher than
87% of the 444 Companies
in the Global Biotechnology industry.

( Industry Median: 128.57 vs. INCY: 23.92 )
Ranked among companies with meaningful Days Inventory only.
INCY' s Days Inventory Range Over the Past 10 Years
Min: 14.49  Med: 122.28 Max: 323.15
Current: 23.92
14.49
323.15
Days Sales Outstanding 43.09
INCY's Days Sales Outstanding is ranked higher than
67% of the 607 Companies
in the Global Biotechnology industry.

( Industry Median: 62.37 vs. INCY: 43.09 )
Ranked among companies with meaningful Days Sales Outstanding only.
INCY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 12.25  Med: 38.86 Max: 6447.52
Current: 43.09
12.25
6447.52
Days Payable 388.07
INCY's Days Payable is ranked higher than
90% of the 444 Companies
in the Global Biotechnology industry.

( Industry Median: 57.77 vs. INCY: 388.07 )
Ranked among companies with meaningful Days Payable only.
INCY' s Days Payable Range Over the Past 10 Years
Min: 407.13  Med: 7019.64 Max: 32457.1
Current: 388.07
407.13
32457.1

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 270.03
INCY's Price/Net Current Asset Value is ranked lower than
99% of the 871 Companies
in the Global Biotechnology industry.

( Industry Median: 4.83 vs. INCY: 270.03 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
INCY' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.23  Med: 10.69 Max: 3615
Current: 270.03
1.23
3615
Price/Tangible Book 71.12
INCY's Price/Tangible Book is ranked lower than
98% of the 1012 Companies
in the Global Biotechnology industry.

( Industry Median: 4.22 vs. INCY: 71.12 )
Ranked among companies with meaningful Price/Tangible Book only.
INCY' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.91  Med: 6.08 Max: 340.56
Current: 71.12
0.91
340.56
Price/Median PS Value 0.85
INCY's Price/Median PS Value is ranked higher than
60% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 0.96 vs. INCY: 0.85 )
Ranked among companies with meaningful Price/Median PS Value only.
INCY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.1  Med: 0.70 Max: 8.65
Current: 0.85
0.1
8.65
Price/Graham Number 33.11
INCY's Price/Graham Number is ranked lower than
99% of the 214 Companies
in the Global Biotechnology industry.

( Industry Median: 2.88 vs. INCY: 33.11 )
Ranked among companies with meaningful Price/Graham Number only.
INCY' s Price/Graham Number Range Over the Past 10 Years
Min: 4.27  Med: 7.78 Max: 176.63
Current: 33.11
4.27
176.63
Earnings Yield (Greenblatt) (%) 0.60
INCY's Earnings Yield (Greenblatt) (%) is ranked higher than
76% of the 1169 Companies
in the Global Biotechnology industry.

( Industry Median: -9.30 vs. INCY: 0.60 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
INCY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 0.60 Max: 1.2
Current: 0.6
0.1
1.2

More Statistics

Revenue (TTM) (Mil) $857.9
EPS (TTM) $ 0.25
Beta0.60
Short Percentage of Float4.55%
52-Week Range $55.00 - 133.62
Shares Outstanding (Mil)187.62

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Dec16 Dec17 Dec18
Revenue (Mil $) 1,043 1,413 1,557
EPS ($) 0.27 1.35 1.81
EPS w/o NRI ($) 0.27 1.35 1.81
EPS Growth Rate
(3Y to 5Y Estimate)
170.10%
Dividends Per Share ($)
» More Articles for INCY

Headlines

Articles On GuruFocus.com
Vanguard Health Care Fund Ups Stake in High-Conviction Stocks May 10 2016 
Market-Beating Vanguard Health Care Fund Adds Shares to 5 Positions May 03 2016 
Vanguard Boosts Stake in Incyte in 1st Quarter May 02 2016 
Frank Sands Acquires Stake in Netflix Feb 23 2016 
Top Insider Trades of the Past Week Feb 19 2016 
The Best-Performing Stocks Among Vanguard Health Care Fund's Holdings Nov 04 2015 
Amazon Among Ken Fisher's Best Performing Stocks Oct 19 2015 
Weekly CFO Sells Highlight: Aramark, Incyte Corp Ltd., Facebook Inc. Jun 09 2014 
Weekly Insider Sells Highlight: ARMK, INCY, ESC, HUN Jun 08 2014 
Weekly Insider Sells Highlight: CPN, INCY, GPK, CODE Feb 23 2014 

More From Other Websites
What Do Analysts Recommend for United Therapeutics? Jul 22 2016
Eli Lilly (LLY) May Beat Q2 Earnings: Will the Stock Gain? Jul 21 2016
INCYTE CORP Files SEC form 8-K, Change in Directors or Principal Officers Jul 19 2016
Updated Data for Epacadostat, Incyte’s Selective IDO1 Inhibitor, Accepted for Presentation at the... Jul 19 2016
Incyte to Report Second Quarter Financial Results Jul 14 2016
Incyte to Report Second Quarter Financial Results Jul 14 2016
[$$] Incyte, a Biotech Acquisition Target Jul 14 2016
Biotech: 'We Would Not Be Surprised to See Volatility Continue' Jul 13 2016
Coverage initiated on Incyte by RBC Capital Mkts Jul 13 2016
INCYTE CORP Files SEC form 8-K/A, Financial Statements and Exhibits Jul 01 2016
Incyte Gains on Jakafi's Breakthrough Status for Acute GVHD Jun 24 2016
Incyte Reports Epacadostat Combination Study Initiation Jun 23 2016
Incyte Gets FDA Approval For Breakthrough Therapy Status For Its Ruxolitinib Jun 23 2016
FDA Grants Breakthrough Therapy Designation for Incyte’s Ruxolitinib (Jakafi®) in Acute... Jun 23 2016
FDA Grants Breakthrough Therapy Designation for Incyte’s Ruxolitinib (Jakafi®) in Acute... Jun 23 2016
Incyte Announces First Patient Treated in ECHO-301 Phase 3 Study Jun 22 2016
Incyte Announces First Patient Treated in ECHO-301 Phase 3 Study Jun 22 2016
Incyte Corp. – Value Analysis (NASDAQ:INCY) : June 21, 2016 Jun 21 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)